세계의 비오피오이드 진통제 시장 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 통증별, 투여 경로별, 유통 경로별, 지역별, 부문 예측(2025-2030년)

Non-opioid Pain Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Pain, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,221,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,602,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,366,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

비 오피오이드 진통제 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 비오피오이드 진통제 시장 규모는 2030년까지 703억 달러에 이르며, 2025-2030년의 CAGR은 7.69%를 나타낼 것으로 예측되고 있습니다.

이 성장은 신규 비오피오이드 진통제의 견고한 제품 파이프라인과 결합하여 염증성 질환의 유병률 증가로 인한 것입니다. 가 골관절염을 앓고 있으며 미국 척추염 협회에 따르면 미국에서는 약 320만 명이 어떤 형태로 척추관절증을 앓고 있습니다.

정부와 비영리 단체는 통증을 완화시키는 의약품 수요 증가에 대응하기 위해 NSAIDs와 같은 오피오이드를 대체하는 보다 안전한 의약품의 사용을 촉진하기 위한 노력을 실시했습니다. 2022년 2월, 미국 FDA는 30일 동안 지속되는 급성 통증의 치료로 NSAIDs를 개발 약사에 권고하는 가이드 라인안을 발표했습니다. 이 이니셔티브는 오피오이드 과잉 섭취 환자의 예방, 감소, 치료, 회복에 초점을 맞춘 정부의 「HHS 과잉 섭취 방지 전략」의 일환입니다. 따라서 예측 기간 동안 NSAID 의약품에 대한 수요가 촉진될 것으로 예측됩니다.

시장의 주요 진출기업은 통증 관리를 위한 NSAIDs 수요 증가에 대응하기 위해 혁신적인 기술을 적극적으로 개발하고 있습니다. 예를 들어, 2021년 6월, 애리조나 대학은 고통받는 환자의 치료를 위해 옥시토신 아날로그를 개발했습니다. 이것은 생물학적으로 이용 가능한 비 오피오이드 진통제이며 흡입 투여가 가능합니다. 이러한 혁신적인 제품의 개발은 비 오피오이드 진통제 치료 시장의 성장을 가속할 것으로 예상됩니다.

2022년 9월, 미국 FDA는 태아에 신장 장애가 일어날 가능성이 높기 때문에 임신 20주에 비오피오이드 진통제 치료를 피할 것을 권장했습니다. 이러한 각국 정부의 이니셔티브는 NSAIDs의 제형을 제한할 수 있으며, 비오피오이드 진통제 시장의 성장을 억제할 수 있습니다.

기업은 비오피오이드 진통제의 침투를 높이기 위해 신제품 개발, 우에시, 제휴 등의 전략을 채용하고 있습니다. 예를 들어, Vertex Pharmaceuticals는 2022년 3월 2상 임상 검사에서 비오피오이드 정제가 수술 후 급성 통증을 유의하게 완화시킨다는 좋은 결과를 발표했습니다. 성공적인 연구와 후속 제품의 승인은 예측 기간 동안 비 오피오이드 진통제 치료 시장의 성장을 가속할 것으로 예상됩니다.

이 시장은 경쟁이 심하고 다수의 진출기업이 존재하기 때문에 예측 기간 중 시장 경쟁은 고수준이 될 것으로 예상됩니다. 제네릭 NSAID 제품을 제조하는 주요 기업으로는 GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Johnson & Johnson Services, Inc. 등이 있습니다.

비 오피오이드 성 진통제 시장 보고서 하이라이트

• 2024년에는 NSAIDs 부문이 최대 시장 점유율을 차지하고 진통제에 대한 높은 수요와 최근 여러 NSAIDs의 상업화에 의해 예측 기간 동안에도 그 우위성을 유지할 것으로 예측됩니다.
• 2024년에는 만성 통증이 가장 높은 점유율을 차지합니다.
• 투여 경로 유형별로 경구 NSAIDs 제품은 투여가 쉽고 시장에서 널리 이용 가능하기 때문에 경구 투여 부문이 2024년에 가장 높은 점유율을 차지했습니다.
• 유통 채널별로 소매 약국이 2024년에 54.39%의 점유율을 차지하고 시장을 독점할 것으로 예상됩니다. 환자가 용이하게 입수할 수 있는 것에 기인하고 있습니다.
• 아시아태평양은 NSAIDs 제품의 보급률의 상승, 가처분 소득 증가, 신흥 국가에서의 염증성 질환의 유병률의 높이 등으로부터 예측 기간 중에 가장 빠른 성장이 전망되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 비오피오이드 진통제 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비오피오이드 진통제 시장 분석 도구
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석
• 가격 분석

제4장 비오피오이드 진통제 시장 : 약제 클래스별, 추정·동향 분석

• 부문 대시보드
• 세계의 비 오피오이드 진통제 시장 : 약물 클래스의 변동 분석
• 약제별, 클래스별 수익
• NSAID
  • 비선택적 NSAID
  • 선택적 COX-2 억제제
• 아세트아미노펜
• 국소 마취제
• 기타

제5장 비오피오이드 진통제 시장 : 통증별, 추정·동향 분석

• 부문 대시보드
• 세계의 비 오피오이드 진통제 시장 : 통증의 변동 분석
• 통증, 수익
• 수술 후 통증
• 암 통증
• 만성 통증
• 기타 통증

제6장 비오피오이드 진통제 시장 : 투여 경로별, 추정·동향 분석

• 부문 대시보드
• 세계의 비 오피오이드 진통제 시장 : 투여 경로의 변동 분석
• 투여 경로별 수익
• 경구
• 국소
• 주사
• 기타

제7장 비오피오이드 진통제 시장 : 유통 채널별, 추정·동향 분석

• 부문 대시보드
• 세계의 비 오피오이드 진통제 시장 : 유통 채널의 변동 분석
• 유통 채널별, 수익
• 병원 약국
• 소매 약국
• 온라인 약국

제8장 비오피오이드 진통제 시장 : 약제 클래스, 진통, 투여 경로, 유통 채널에 의한 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2024년
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Sun Pharmaceutical Industries Ltd
  • GSK plc.
  • Pfizer Inc.
  • Perrigo Company plc.
  • LNK International, Inc.
  • Cipla Inc.
  • Johnson & Johnson Services, Inc.
  • Pacira Pharmaceuticals, Inc.
  • Pierrel

JHS

영문 목차

영문목차

Non-opioid Pain Treatment Market Growth & Trends:

The global non-opioid pain treatment market size is expected to reach USD 70.30 billion by 2030, registering a CAGR of 7.69% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis.

Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government's "HHS Overdose Prevention Strategy" which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period.

Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth.

In September 2022, the U.S. FDA recommended avoiding non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth.

Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth during the forecast period.

The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others.

Non-opioid Pain Treatment Market Report Highlights:

• In 2024, the NSAIDs segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period owing to the high demand for pain treatment and the commercialization of multiple NSAIDs in recent years
• Chronic pain was the accounted for highest share in 2024. Factors such as increasing product approvals, the high incidence rate of chronic pain, and high R&D initiatives for launching innovative NSAIDs products are leading to its dominance
• Based on route of administration type, the oral segment accounted for the highest share in 2024 owing to the easy administration and wide availability of orally administered NSAIDs products in the market
• Based on the distribution channel, retail pharmacies are expected to dominate the market with a 54.39% share in 2024. This dominance can be attributed to the presence of a large number of generic NSAIDs and their easy accessibility to patients due to the large presence of retail pharmacies network
• Asia Pacific region is expected to experience the fastest growth during the forecast period owing to an increase in penetration of NSAIDs products, rise in disposable income, and high disease prevalence of inflammatory diseases in developing countries

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Pain
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class and pain outlook
  • 2.2.2. Route of administration and distribution channel outlook
• 2.3. Competitive Insights

Chapter 3. Non-opioid Pain Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High prevalence of chronic & inflammatory diseases globally
    • 3.2.1.2. Increasing product approvals and launches
    • 3.2.1.3. Supportive regulatory and reimbursement policies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulations
    • 3.2.2.2. Side-effects associated with drug
• 3.3. Non-opioid Pain Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis

Chapter 4. Non-opioid Pain Treatment Market: Drug Class Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Non-opioid Pain Treatment Market: Drug Class Movement Analysis
• 4.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Drug, Class Revenue (USD Million)
• 4.4. NSAIDs
  • 4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Non-Selective NSAIDs
    • 4.4.2.1. Non-Selective NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Selective COX-2 Inhibitors
    • 4.4.3.1. Selective COX-2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Acetaminophen
  • 4.5.1. Acetaminophen market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Local Anesthetics
  • 4.6.1. Local Anesthetics market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other Drug Class
  • 4.7.1. Others drug class market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Non-opioid Pain Treatment Market: Pain Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Non-opioid Pain Treatment Market: Pain Movement Analysis
• 5.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Pain, Revenue (USD Million)
• 5.4. Post-operative Pain
  • 5.4.1. Post-operative pain market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cancer Pain
  • 5.5.1. Cancer pain market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Chronic Pain
  • 5.6.1. Chronic pain market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Other Pain
  • 5.7.1. Other pain market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Non-opioid Pain Treatment Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Non-opioid Pain Treatment Market: Route of Administration Movement Analysis
• 6.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 6.4. Oral
  • 6.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Topical
  • 6.5.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Injectable
  • 6.6.1. Injectable market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Other Route of Administration
  • 6.7.1. Other route of administration market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Non-opioid Pain Treatment Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Non-opioid Pain Treatment Market: Distribution Channel Movement Analysis
• 7.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 7.4. Hospitals Pharmacies
  • 7.4.1. Hospitals pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Non-opioid Pain Treatment Market: Regional Estimates & Trend Analysis By Drug Clas, Pain, Route of Administration, and Distribution Channel

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2024
  • 9.3.2. Novartis AG
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Teva Pharmaceutical Industries Limited
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Teva Pharmaceutical Industries Limited
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Sun Pharmaceutical Industries Ltd
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. GSK plc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Pfizer Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Perrigo Company plc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. LNK International, Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Cipla Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Johnson & Johnson Services, Inc.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Pacira Pharmaceuticals, Inc.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Pierrel
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives

관련자료